Drawing for NABOTA

USPTO serial 85902409

NABOTA

Reviewed by CopyMark Law Group

Reg. 4535957Status 711
Filing date
Status date
Registration date
May 27, 2014
Examiner
GILBERT, REBECCA L
Law office
TMEG LAW OFFICE 103

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with NABOTA?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

John M. Kim

John M. Kim IPLA, LLP4445 Eastgate Mall, Suite 200San Diego, CA 92121UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Botulinum toxin for medical use for use in the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, pelvic pain and urge type dysfunction; Pharmaceutical preparations, namely, acne medications, acne treatment preparations, adrenal hormone preparations, alcohol for topical use, allergy and allergy relief medications, analgesics, androgen preparations, anesthetics for surgical and non-surgical use, antacids, bactericides, antiarrhythmics, antibiotics, anticoagulants, anticonvulsants, antidepressants, antidiabetic preparations, antivirals, anti-cancer preparations, anti-infectives, anti-inflammatories, antipyretics, antibacterial pharmaceuticals, calcium channel blockers, beta blockers, chemical compounds for drug delivery, eye drops, eye patches for medical purposes, hair growth stimulants, vaccines, vaccine adjuvants, vaccine stabilizers, diuretics, amino acids for medical purposes; Medicines for the treatment of gastrointestinal diseases; chemical preparations for pharmaceutical purposes for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, pelvic pain and urge type dysfunction; chemico-pharmaceutical preparations for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, pelvic pain and urge type dysfunction; drugs for medical purposes for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, pelvic pain and urge type dysfunction; Medicines for human purposes for the treatment of glabellar lines, muscular rigidity, blepharospasm, cervical dystonia, hyperhidrosis, strabismus, prostate disorder, migraine headache, urge incontinence, urinary retention that is secondary to a hypertrophied bladder neck, recalcitrant voiding dysfunction, urge incontinence, neurogenic bladder dysfunction, pelvic pain and urge type dysfunction; pharmaceutical preparations for activating cellular function; Adjuvants for medical purposes; pharmaceutical preparations for central nerve treatment; pharmaceutical preparations for diagnosis; dermatological pharmaceutical products; pharmaceutical preparations for treating skin disorders; antibiotic preparations; pharmaceutical preparations for respiratory organs; pharmaceutical preparations for chemical disorder treatmentSECTION 7(e) - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Jan 15, 2021NCS7NOTICE OF CANCELLATION SEC. 7 SURRENDER EMAILED—
Jan 14, 2021C7..CANCELLED SECTION 7-TOTAL—
Jan 8, 2021APRECASE ASSIGNED TO POST REGISTRATION PARALEGAL—
Oct 19, 2020C7RFREQUEST FOR SECT 7 TOTAL SURRENDER FILED—
Oct 19, 2020ES7STEAS SECTION 7 SURRENDER RECEIVED—
Oct 19, 2020CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
Oct 19, 2020TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Oct 19, 2020ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Oct 19, 2020REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Oct 19, 2020COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
May 27, 2019REM1COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED—
May 27, 2014R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Mar 11, 2014NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Mar 11, 2014PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Feb 19, 2014NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Feb 4, 2014PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Jan 29, 2014CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Jan 28, 2014TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 28, 2014CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 21, 2014ALIEASSIGNED TO LIE—
Dec 30, 2013TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 30, 2013GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 30, 2013GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 30, 2013CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 29, 2013DOCKASSIGNED TO EXAMINER—
Apr 18, 2013NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Apr 16, 2013NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance